Biomarkers of response to treatment in acromegaly

Expert Rev Endocrinol Metab. 2023 Dec 11:1-11. doi: 10.1080/17446651.2023.2293107. Online ahead of print.ABSTRACTINTRODUCTION: Medical treatment of acromegaly is based in a `trial and error` approach. First-generation somatostatin receptor ligands (fg-SRL) are prescribed as first-line medical therapy to the vast majority of patients, despite lack of disease control in approximately 60% of patients. However, other drugs used in acromegaly treatment are available (cabergoline, pasireotide and pegvisomant).AREAS COVERED: In this article, we review and discuss the biomarkers of response to medical treatment in acromegaly.EXPERT OPINION: Biomarkers for fg-SRL that can already be applied in clinical practice are: gender, age, pretreatment GH and IGF-I levels, cytokeratin granulation pattern, and the expression of somatostatin receptor type 2. Using biomarkers of response could guide treatment towards precision medicine with greater efficacy and lower costs.PMID:38078447 | DOI:10.1080/17446651.2023.2293107
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Authors: Source Type: research